Boehringer has entered into a collaboration with Sino Biopharm, focusing on antibody-drug conjugate (ADC) and T-cell engager (TCE) technologies across six programmes. This partnership is valued at up to $7.4 billion, indicating a significant investment in oncology development.
The collaboration may enhance both companies’ capabilities in delivering innovative cancer therapies. For manufacturers and suppliers, this deal could signal increased demand for ADC and TCE technologies, potentially impacting supply chains and production strategies in the oncology sector.
Source: pharmaceutical-technology.com · Image: Leuankallio Simo 20140713 by Estormiz, CC0, via Wikimedia Commons
Explore deeper: the API & FDF Intelligence database is more than a directory.
It combines global coverage of APIs, excipients, and finished dosage forms with real market intelligence.
You’ll find:
– Price ranges for APIs, excipients, and formulations.
– DMF, CEP, and GMP compliance status.
– Manufacturer portfolios by product and geography.
– Direct contacts for every producer and FDF holder, ready for outreach.
Instead of scattered spreadsheets and endless searches, the entire picture is a few clicks away. Subscription starts at an accessible rate — see how much time and budget you save by centralizing everything.
Start your 7-day trial and see what the database can do →
Start your 7-day trial and see what the database can do →
